Early trial tests drug duo to fight tough breast cancers
NCT ID NCT03742245
Summary
This early-stage study is testing the safety and initial effectiveness of combining two drugs, olaparib and vorinostat, for adults with advanced breast cancer that has returned after treatment or spread. The goal is to find the safest dose and see if blocking two cancer cell repair mechanisms together works better. The trial involves a small group of participants and focuses first on safety before measuring how tumors respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.